FASLG and neoplasm: To elucidate the role of IL-9 in the antitumor effects of these cells, we subcutaneously challenged Il9r−/− mice with B16F10-OVA tumor cells and found that neither FasL + p38i-TH9 nor FasL-TH9 could inhibit tumor progression (Fig. 7j, k).